The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Malignancies exhibited moderate to strong nuclear immunoreactivity. Few prostate, testicular and skin cancers were weakly stained or negative.
Malignant cells displayed moderate to strong nuclear immunoreactivity. Cytoplasmic staining was observed in several cases.
A majority of the malignant cells displayed moderate nuclear/nucleolar immunoreactivity with an additional cytoplasmic staining in some cases. Most lymphomas, along with several cases of melanomas, squamous cell carcinomas, colorectal, liver and endometrial cancers showed strong staining.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
One antibody yielding a staining pattern which is consistent with gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
